Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,575.83
(
-0.74%
)
US TECH 100
23,615.20
(
-0.76%
)
Dow Jones
45,802.76
(
-0.91%
)
Brent Oil
105.66
(
-0.87%
)
Bitcoin
69,705.47
(
-2.16%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: wallstarb post# 84944

Monday, 10/12/2009 5:39:06 PM

Monday, October 12, 2009 5:39:06 PM

Post# of 257259

MNTA should just offer to pay the FDA the standard NDA fee - grease the wheels a bit! Seems a tad unfair that FoBs can end up in regulatory limbo for a near indefinite period of time.

Generic Lovenox is not an FoB. Perhaps you meant to say that the Lovenox application is an ANDA, which does not have a formal review timeline.

If there were a way to expedite an ANDA review by paying a fee, I’m sure NVS (the official applicant in this case) would have done that.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now